On October 22, 2021 Chimeric Therapeutics (ASX:CHM, "Chimeric"), a clinical-stage cell therapy company and the ASX leader in cell therapy, reported the successful completion of manufacturing for CHM 2101 research grade plasmids, a critical first step in the development of CDH17 CAR T (Press release, Chimeric Therapeutics, OCT 22, 2021, View Source [SID1234591763]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Manufacturing of CAR T therapies is dependent upon plasmids and viral vectors that hold the genetic instructions for each specific CAR T product. Plasmids are small DNA molecules that carry genetic instructions and their successful manufacture marks an important early step for all CAR T therapies.

In collaboration with the University of Pennsylvania, all of the research grade helper and transfer plasmids for the CDH17 CAR T have been completed and released. The achievement of this first step in CAR T manufacturing enables progression to research vector manufacturing, GMP plasmid and vector manufacturing and advancement of technical operations in readiness for the CDH17 CAR T phase 1 clinical trial.

Chimeric’s CEO and Managing Director Jennifer Chow said: "We are very pleased that we have been able to achieve this key first step so rapidly after licensing. This accomplishment speaks to the commitment and drive that the Chimeric and University of Pennsylvania teams share to move this important CAR T forward to Phase 1 clinical trials."

In addition to commencing the CDH17 CAR T Phase 1 trial in 2022, Chimeric is also progressing its CLTX CAR T Phase 1 clinical trial in glioblastoma (brain cancer) at The City of Hope Cancer Centre in California, where patients are now receiving second dose levels.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper